The Drug-Eluting Stent Information Gap

Authors

  • Cynthia A. Yock MS,

    1. From the Center for Primary Care and Outcomes Research1 and the Department of Bioengineering and Division of Cardiovascular Medicine2, Stanford University School of Medicine, Stanford, CA
    Search for more papers by this author
  • Paul G. Yock MD

    1. From the Center for Primary Care and Outcomes Research1 and the Department of Bioengineering and Division of Cardiovascular Medicine2, Stanford University School of Medicine, Stanford, CA
    Search for more papers by this author

Cynthia Yock, MS, Center for Primary Care and Outcomes Research, 1 17 Encina Commons, Stanford, CA 94305- 6019; e-mail: yock@healthpolicy.stanford.edu

Abstract

Drug-eluting stents are quickly replacing bare-metal stents as the arterial revascularization device of choice. Because nearly all the information we have about patient outcomes with drug-eluting stents is from trials designed for US Food and Drug Administration approval, we are missing some of the information critical to a more comprehensive understanding of how these new devices will perform at the population level.

Ancillary